Literature DB >> 11020019

Lp(a) is increased in hemodialysis patients according to the type of dialysis membrane: a 2-year follow-up study.

M E Diop1, B Viron, S Bailleul, G Lefevre, H Fessi, J Maury, J Etienne, R Couderc.   

Abstract

AIMS: Patients with chronic renal failure treated by hemodialysis develop lipoprotein abnormalities that may contribute to their increased risk ofatherosclerosis. This study shows lipid parameter follow-up procedure according to the type of dialysis membrane in an unselected population of 33 hemodialysis patients. PATIENTS AND METHODS: The study included 33 patients with end-stage renal disease and 110 healthy blood bank donors of Tenon Hospital. Cholesterol and triglycerides were determined by enzymatic methods, apoA-I, apoB by immunoturbidimetry and Lp(a) by immunonephelemetry. Apo(a) phenotyping was performed by agarose gel electrophoresis followed by immunoblotting. Patients and controls subjects were estimated by Student's t- and chi2-tests.
RESULTS: Patients dialyzed with low-flux membranes had Lp(a) concentrations higher than patients dialyzed with high-flux membranes. Patients dialyzed with polyacrylonitrile membranes (AN 69) had an apoA-I concentration significantly lower than patients dialyzed with hemophane or polysulfone membranes. We also confirmed some of the lipid abnormalities and high Lp(a) concentrations in ESRD patients.
CONCLUSION: These results may contribute to a more rational choice of the dialysis membrane in hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020019

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  2 in total

Review 1.  High-flux versus low-flux membranes for end-stage kidney disease.

Authors:  Suetonia C Palmer; Kannaiyan S Rabindranath; Jonathan C Craig; Paul J Roderick; Francesco Locatelli; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

2.  Effects of renal replacement therapy on plasma lipoprotein(a) levels.

Authors:  Sylvia Rosas; Marshall Joffe; Megan Wolfe; Kenneth Brayman; Daniel J Rader
Journal:  Am J Nephrol       Date:  2007-12-05       Impact factor: 3.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.